Pull to refresh
Logo
FDA rejects Capricor's Duchenne cell therapy again, citing compromised trial data

FDA rejects Capricor's Duchenne cell therapy again, citing compromised trial data

Rule Changes

A second complete response letter faults Study HOPE-3's statistics and blinding, not just the size of the benefit

Overview

Updated 12 minutes ago

Deramiocel was built to slow the heart and muscle damage that makes Duchenne muscular dystrophy fatal. On Friday the Food and Drug Administration turned it down for the second time in 16 months, and this rejection did not hinge on whether the benefit was big enough. The agency said the trial data could not be trusted.

That distinction decides what happens next. A missed endpoint can be answered with a larger or longer study. A finding that a sponsor changed its statistical plan after the fact and broke study blinding cannot be fixed by reanalyzing the same numbers, which is the position the FDA took in a statement and a complete response letter dated Nov. 20.

Why it matters

A missed endpoint can be answered with another trial. A data-integrity finding means the trial already run cannot be used.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

2
FDA rejections of deramiocel
The first came in July 2025, the second in November 2026.
80%
Drop in Capricor shares
The stock fell by roughly four-fifths after the rejection became public.
106
Patients in Study HOPE-3
Boys and young men aged 10 to 22 at 20 U.S. sites, most of them no longer able to walk.
~15,000
Americans with Duchenne muscular dystrophy
A genetic disorder that mostly affects boys.
$198.5M
Capricor cash and securities
Balance as of Sept. 30, 2026, which the company says funds at least 12 more months of operations.

Voices

Curated perspectives — historical figures and your fellow readers.

Sign up to generate historical perspectives on this story.

People Involved

Organizations Involved

Timeline

July 2025 November 2026

6 events Latest: Yesterday
Tap a bar to jump to that date
  1. FDA turns back deramiocel a second time over data integrity

    Latest Regulatory

    The agency said serious violations in Study HOPE-3, including post hoc statistical changes and broken blinding, leave the data unreliable and unable to be fixed after the fact. The complete response letter and a Regulatory Responsibility Letter are dated Nov. 20.

  2. Capricor shares fall about 80%

    Market

    The rejection wiped out most of the company's market value and put a lease tied to a potential launch in question.

  3. Review extended as Capricor narrows its request

    Regulatory

    The FDA pushed its target date to Nov. 22 after Capricor said it would seek approval for upper limb function instead of cardiomyopathy. Capricor later filed a major amendment with 24-month open-label extension data.

  4. Advisers side with FDA staff, and a journal paper complicates the case

    Advisory committee

    A majority of the outside panel concluded the trial had not shown clear evidence of effectiveness. The same day, Lancet published HOPE-3 results that conflicted with earlier company claims, prompting a clarification filing.

  5. Capricor says HOPE-3 hit both main goals

    Clinical trial

    The company reported deramiocel preserved upper limb and heart function in the late-stage study.

  6. FDA rejects deramiocel the first time

    Regulatory

    The agency said Capricor had not proven the therapy works and needed more data. The company said it was blindsided.

Scenarios

1

Capricor commits to a new pivotal trial

Possible Resolves by End of 2027

Discussed by: Capricor's own statements that it is evaluating next steps, as relayed by the Muscular Dystrophy Association

The rejection does not bar a new study; it bars approval on the existing one. A fresh randomized, blinded trial with a statistical plan locked before unblinding would give the FDA data it can review. That costs years and tens of millions of dollars, and Capricor has said only that it is evaluating its options.

2

Capricor contests the inspection findings through formal channels

Possible Resolves by Apr 30, 2027

Discussed by: Capricor's public dispute of the FDA's evidence assessment, and the Regulatory Responsibility Letter's invitation to respond

The Nov. 20 Regulatory Responsibility Letter gives Capricor a formal route to answer the inspection findings, and a dispute-resolution meeting with agency leadership is a separate track. Neither changes the underlying trial data, so any success depends on the FDA accepting that the violations did not affect the results.

3

Capricor shelves deramiocel or sells the program

Possible Resolves by Q2 2027

Discussed by: Analysts covering the 80% share drop, and the company's own statement that operating expenses are under review

Capricor ended September with $198.5 million and says that funds 12 months of operations. A second rejection of the lead asset makes deprioritizing, out-licensing, or selling the program a live option, especially with a lease that either party can terminate if approval on acceptable terms does not arrive by Dec. 31.

4

FDA approves deramiocel without a new trial

Unlikely Resolves by End of 2027

Discussed by: Trial investigators who signed a letter urging approval, and the argument that rare-disease reviews warrant regulatory flexibility

More than two dozen investigators and physicians wrote to regulators arguing that a rejection would show inflexibility toward rare disease. But the agency's stated ground is that the data are unreliable, not that the benefit is modest, and it has said that defect cannot be repaired retrospectively. Approval on the current record would require the FDA to reverse its own inspection conclusions.

Historical Context

2 moments from history that rhyme with this story — and how they unfolded.

April-September 2016

Eteplirsen and Duchenne's accelerated approval (2016)

Sarepta Therapeutics sought approval of eteplirsen for Duchenne based on a small study and a surrogate measure of dystrophin production. FDA reviewers objected, and an advisory committee voted 7-6 that the evidence did not support approval.

Then

The FDA granted accelerated approval in September 2016 and required a confirmatory trial.

Now

Accelerated approval kept the drug available while the argument over its evidence continued, and the case became a reference point in debates over how much proof rare-disease drugs need.

Why this matters now

It shows the FDA will accept thin evidence in Duchenne when the fight is over how to read the data. Deramiocel's rejection is about whether the data can be believed at all.

2010-2015

Duke's genomic cancer trials (2010)

Duke University oncologists assigned chemotherapy in clinical trials using gene-expression signatures developed by researcher Anil Potti. Outside biostatisticians found errors in the underlying analysis, and the trials were suspended in 2010.

Then

The studies were halted, several papers were retracted, and Potti resigned.

Now

The episode is used in research-methods training as an example of how analysis errors, not just disappointing results, can end a clinical program.

Why this matters now

It explains why regulators treat mid-study changes to an analysis plan and broken blinding as disqualifying rather than debatable.

Sources

(6)